Your session is about to expire
← Back to Search
KRT-232 for Myelofibrosis (BOREAS Trial)
Phase 2 & 3
Recruiting
Research Sponsored by Kartos Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)
High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System (DIPSS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 months
Awards & highlights
BOREAS Trial Summary
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Who is the study for?
This trial is for patients with myelofibrosis who haven't responded to JAK inhibitor treatment. They should have a performance status score of 2 or less, indicating they can perform daily activities with some effort. The trial excludes those with significant heart issues, recent major organ transplants, brain injuries or strokes within the past 6 months, prior splenectomy, and previous treatments targeting MDM2 or p53.Check my eligibility
What is being tested?
The study tests KRT-232 against Best Available Therapy (BAT) in myelofibrosis patients unresponsive to JAK inhibitors. Phase 2 determines the optimal dose of KRT-232; Phase 3 compares its effectiveness to BAT chosen by physicians. Participants are randomly assigned in a 2:1 ratio favoring KRT-232 and may switch from BAT to KRT-232 if needed.See study design
What are the potential side effects?
While specific side effects for KRT-232 aren't listed here, similar drugs often cause fatigue, nausea, diarrhea, liver function changes and potential blood cell count alterations. Side effects vary based on individual health conditions and drug interactions.
BOREAS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a form of myelofibrosis.
Select...
My condition is classified as high, intermediate-2, or intermediate-1 risk.
Select...
I have been treated with a JAK inhibitor, but it did not work for me.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
BOREAS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
(Part A Only) Spleen Volume Reduction (SVR)
(Part B Only) Spleen Volume Reduction (SVR)
Secondary outcome measures
(Part A only) Improvement in Total Symptom Score (TSS)
Spleen
Blood Transfusion
+4 moreBOREAS Trial Design
6Treatment groups
Experimental Treatment
Active Control
Group I: Part B Arm 1 KRT-232Experimental Treatment1 Intervention
KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Group II: Part A Cohort 4bExperimental Treatment1 Intervention
KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
Group III: Part A Cohort 3Experimental Treatment1 Intervention
KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Group IV: Part A Cohort 2Experimental Treatment1 Intervention
KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Group V: Part A Cohort 1Experimental Treatment1 Intervention
KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Group VI: Part B Arm 2 Best Available TherapyActive Control1 Intervention
Best available therapy at the discretion of the investigator, on a 28-day cycle.
Find a Location
Who is running the clinical trial?
Kartos Therapeutics, Inc.Lead Sponsor
15 Previous Clinical Trials
1,065 Total Patients Enrolled
3 Trials studying Primary Myelofibrosis
204 Patients Enrolled for Primary Myelofibrosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have previously received MDM2 or p53-targeted therapy.I have had or plan to have a stem cell transplant from a donor.I have had my spleen removed.I have not had any major bleeding or brain bleeding in the last 6 months.I have not had a stroke or temporary paralysis in the last 6 months.I have been diagnosed with a form of myelofibrosis.My condition is classified as high, intermediate-2, or intermediate-1 risk.I have been treated with a JAK inhibitor, but it did not work for me.I can take care of myself and am up and about more than 50% of my waking hours.I have not had radiation to my spleen in the last 3 months.I have had a major organ transplant.My previous treatment with a JAK inhibitor did not work and I can still care for myself.
Research Study Groups:
This trial has the following groups:- Group 1: Part A Cohort 2
- Group 2: Part A Cohort 4b
- Group 3: Part B Arm 2 Best Available Therapy
- Group 4: Part B Arm 1 KRT-232
- Group 5: Part A Cohort 1
- Group 6: Part A Cohort 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Do we have any precedent for using KRT-232 in this way?
"KRT-232 was first researched in 2017 at Huntsman Cancer Institute/University of Utah. There have been 7 completed clinical trials and 13 more are ongoing, with a significant portion taking place in New Haven, Connecticut."
Answered by AI
Are investigators still looking for new participants in this research study?
"This clinical trial, which was first posted on January 15th 2019, is currently seeking patients, as reported on clinicaltrials.gov."
Answered by AI
At how many different locations can people participate in this research?
"Currently, this study has 16 enrolment sites which are actively recruiting patients. These locations include Yale University in New Haven, Tom Baker Cancer Center in Calgary, Summit Medical Group in Florham Park, and other centres across the globe."
Answered by AI
How many people are currently enrolled in this clinical trial?
"In order to move forward with this study, we need 385 individuals that fit the specified bill. These people can come from multiple places, such as Yale University and Tom Baker Cancer Center."
Answered by AI
What is the goal of this research?
"The primary goals of this 24-week study are to observe a reduction in spleen volume (SVR) and, separately, an improvement the total symptom score (TSS). TSS will be measured by the modified MPN-SAF v2.0 over the course of 48 weeks while SVR is only being evaluated during Part B of the trial. Additionally, researchers want to track the rate at which patients become RBC transfusion independent as well as general overall survival rates."
Answered by AI
Who else is applying?
What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Brookdale University Hospital and Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Why did patients apply to this trial?
I've tried jakafi, but it's efficacy is getting weaker. So I apply.
PatientReceived 2+ prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger